Breakthrough Treatment Offers First Disease-Modifying Therapy for Rare Neurological Disorder

The FDA has approved Zanvastro, the first drug that directly targets the underlying cause of Alexander disease, a rare progressive neurological condition affecting fewer than one in a million people worldwide. Clinical trials demonstrated that patients receiving the drug improved motor function and walking speed over the course of a year, with the treatment administered quarterly via injection into the spinal canal. This approval marks a significant milestone after three decades of research, providing patients of all ages from infancy through adulthood with the first option beyond symptom management.

Alexander disease stems from mutations in the GFAP gene, which produces a protein that accumulates abnormally in brain cells called astrocytes. These harmful protein deposits, known as Rosenthal fibers, interfere with the supporting functions these cells provide to neurons, progressively damaging the nervous system's ability to maintain motor control, cognition, and vital automatic functions like breathing and heart rate regulation.

The breakthrough followed a serendipitous discovery in the 1990s when University of Wisconsin researchers created a mouse model intended for different purposes but unexpectedly reproduced the exact pathological hallmarks of the human disease. This connection enabled geneticists to identify GFAP mutations as the disease's cause, shifting focus toward therapies that could suppress the protein's production at its source rather than merely addressing symptoms after damage occurred.